Point Biopharma Global Inc Reports Results For The Quarter Ended In June: Earnings Summary

POINT Biopharma Global

12/08/2022 14:31

* POINT Biopharma Global Inc  PNT.OQ  reported a quarterly
adjusted loss of 27 cents​​ per share for the quarter ended in
June. The mean expectation of five analysts for the quarter was
for a loss of 22 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * POINT Biopharma Global Inc's reported EPS for the quarter
was a
loss of 27 cents​.
    * The mean earnings estimate of analysts had fallen by
about 12.4%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * POINT Biopharma Global Inc shares had risen by 19.1% this
quarter and gained 44.8% so far this year.
    * The company reported a quarterly loss of $24.58 million.
    * Wall Street's median 12-month price target for POINT
Biopharma
Global Inc is $15.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 12
at 01:31 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -0.22          -0.27          Missed
 Mar. 31 2022      -0.21          -0.18          Beat
 Dec. 31 2021      -0.23          -0.16          Beat
 Sep. 30 2021      -0.19          -0.19          Met